Disposition of the Company's earnings

The annual general meeting resolved that no dividend shall be paid to the shareholders for the financial year 2022 and that the funds at disposal of the meeting of SEK 300,839,932.61 shall be balanced in new accounts.

Discharge from liability

The board members and the CEO were granted discharge from liability for the financial year 2022.

Election of board of directors, auditors, and remuneration

The annual general meeting resolved, in accordance with the proposal of the nomination committee, that the number of board members shall be five (5) members without deputies.

The annual general meeting resolved, in accordance with the proposal of the nomination committee, to re-elect Staffan Torstensson, Erland Pontusson, Fredrik Celsing and Johanne Louise Brændgaard and Anna Ljung as board members. It was resolved, in accordance with the proposal of the nomination committee, to re-elect Staffan Torstensson as chairman of the board of directors.

It was resolved, in accordance with the proposal of the nomination committee, to re-elect Öhrlings PricewaterhouseCoopers AB as accounting firm. Öhrlings PricewaterhouseCoopers AB has announced that Johan Engstam will be appointed as auditor in charge.

It was resolved, in accordance with the proposal of the nomination committee, that board renumeration shall be paid with SEK 250,000 to the chairman of the board of directors and SEK 125,000 to each non-employed board member, corresponding to a total of SEK 750,000. It was resolved, in accordance with the proposal of the nomination committee, that renumeration to members of the audit committee shall be paid with SEK 50,000 to the chairman and SEK 25,000 to each member.

Furthermore, it was resolved that renumeration to the auditor shall be paid in accordance with approved invoice.

Authorization of the board of directors to issue shares/warrants/convertible debentures

It was resolved to authorize the board of directors, within the limits of the current articles of association, on one or more occasions, with or without deviation from the shareholders' preferential rights, to resolve on the issue of shares, warrants and/or convertible debentures.

The issue of new shares pursuant to the authorization shall be carried out on customary terms under current market conditions.

For further information:
Rikard Akhtarzand, CEO
+46765-25 90 71
rikard.akhtarzand@addvisegroup.se

Hanna Myhrman, General Counsel
+4670982 92 23
hanna.myhrman@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business - both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the company's Certified Adviser. Additional information is available at www.addvisegroup.com.